Faron, etusivu

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 22, 2026 at 16:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer:
FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation		 City and country of residence:
Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.):
–
5. Date on which the threshold was crossed or reached:
17.6.2026
6. Total positions of person(s) subject to the notification obligation:
% of shares and voting rights
(total of 7.A)		 % of shares and voting rights through financial instruments
(total of 7.B)		 Total of both in % (7.A + 7.B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0.17 8.73 8.90 227,881,315
Position of previous notification (if applicable) 0.12 9.99 10.11
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)		 Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)		 Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)
FI4000153309 0 377,478 0 0.17
– – – – –
– – – – –
SUBTOTAL A 377,478 0.17
B: Financial Instruments according to SMA 9:6a
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash settlement Number of shares and voting rights % of shares and voting rights
Rights of Use n/a n/a n/a 19,584,472 8.59
swaps 15/10/2027 n/a Cash 314,746 0.14
– – – – – –
SUBTOTAL B 19,899,218 8.73

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☒ Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
Bank of America Corporation
NB Holdings Corporation
BofAML Jersey Holdings Limited
BofAML EMEA Holdings 2 Limited
ML UK Capital Holdings Limited
Merrill Lynch International
Bank of America Corporation
NB Holdings Corporation
BAC North America Holding Company
Bank of America, National Association
Bank of America Corporation
NB Holding Corporation
Bofa Securities, Inc 8.59% 8.59%
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.
10. Additional information:
–

Done at London, United Kingdom on 18.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 16:30:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights x
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Timo Syrjälä
City and country of registered office (if applicable) Monaco
4. Full name of shareholder(s) (if different from 3.) v
Name Acme Investments SPF Sarl
City and country of registered office (if applicable) Luxembourg
5. Date on which the threshold was crossed or reached vi: 11.6.2026
6. Date on which issuer notified (DD/MM/YYYY): 16.6.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 6.46% 14.712.470
Position of previous notification (if
applicable)		 7.77% 15.509.443
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 5.544.672 9.167.798 2.43% 4.02%
SUBTOTAL 8. A 14.712.470

6.46%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv		 X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct) 2.43% 2.43%
Acme Investments SPF Sarl (Indirect) 4.02% 4.02%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron has changed 11.6.2026 the way the flagging responsibility is defined by calculating also shares registered and issued to Faron and still owned by company itself. However, shares owned by Faron itself cannot be calculated as capable to vote in shareholders meetings. New total number of Faron shares registered 227.881.315.
Place of completion Monaco
Date of completion 16.6.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer:
FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation		 City and country of residence:
Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.):
–
5. Date on which the threshold was crossed or reached:
12.6.2026
6. Total positions of person(s) subject to the notification obligation:
% of shares and voting rights
(total of 7.A)		 % of shares and voting rights through financial instruments
(total of 7.B)		 Total of both in % (7.A + 7.B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0.12 9.99 10.11 206,411,888
Position of previous notification (if applicable) 0.13 10.07 10.20
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)		 Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)		 Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)
FI4000153309 0 246,335 0 0.12
– – – – –
– – – – –
SUBTOTAL A 246,335 0.12
B: Financial Instruments according to SMA 9:6a
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash settlement Number of shares and voting rights % of shares and voting rights
Rights of Use n/a n/a n/a 20,374,993 9.87
Swaps 15/10/2027 n/a Cash 245,294 0.12
– – – – – –
SUBTOTAL B 20,620,287 9.99

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☒ Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
– – – –
– – – –
– – – –

–

 – – –
– – – –
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.
10. Additional information:

Done at London, United Kingdom on 15.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 15, 2026 at 18:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 11/06/2026
6. Date on which issuer notified (DD/MM/YYYY): 12/06/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 8.88% 12.53% 21.41% 48,784,893
Position of previous notification (if
applicable)		 10.33% 13.84% 24.17%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 20,224,893 28,560,000 8.88% 12.53%
SUBTOTAL 8. A 48,784,893 21,41%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 11,760,000 5.16%
Convertible Bond 12/02/2028 Anytime until maturity 16,800,000 7.37%
SUBTOTAL 8. B 1 28,560,000 12.53%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 8.88% 12.53% 21.41%
CVI Investments, Inc. 8.88% 12.53% 21.41%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 12.06.2026

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

Faron Pharmaceuticals Ltd | Press Release | June 15, 2026 at 09:00:00 EEST

Data continue to demonstrate prolonged durability of response, with median duration of CR reaching 16.1 months in frontline HR‑MDS, supporting the upcoming initiation of the Phase 2b trial

  • Median duration of Complete Remission (CR) in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) extended to 16.1 months with bexmarilimab + azacitidine
  • Frontline HR-MDS treatment achieved an 85% Overall Response Rate (ORR), with 60% of patients achieving full clearance of bone marrow blasts
  • Translational data indicates bexmarilimab drives bone marrow progenitor recovery and adaptive immune recruitment

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announced the poster presentation of updated translational insights and matured clinical efficacy data from its ongoing BEXMAB Phase 1/2 trial at the European Hematology Association (EHA) 2026 Congress, 11-14 June, Stockholm, Sweden. The poster highlights the steady accumulation of clinical and biological evidence validating bexmarilimab, Faron’s first-in-class immunotherapy candidate currently under clinical development for myeloid malignancies.

Enhanced remission durability and blast clearance in treatment-naïve HR-MDS

Data from the treatment-naïve HR-MDS cohort continues to mature positively, reflecting an ORR of 85% and a CR rate of 45%. Following a longer median follow-up of 14.9 months, the trial achieved substantial improvements in the durability and depth of clinical responses. Specifically, median duration of CR reached 16.1 months, indicating durable and clinically meaningful responses. Furthermore, 60% of patients now demonstrate full clearance of bone marrow blasts, a positive increase from the 55% observed in the prior data cut. As previously disclosed, Faron has achieved alignment with the FDA on the use of CR as a key endpoint for the upcoming Phase 2b trial, making the observed CR rate in this study particularly encouraging.

Dr. Mika Kontro, MD, PhD, Associate Professor at the Helsinki University Hospital Comprehensive Cancer Center and Principal Investigator of the BEXMAB trial, said, “These results reinforce the potential of bexmarilimab to deliver clinically meaningful benefit in HR-MDS. A median duration of CR of 16.1 months in frontline patients is an encouraging signal, and the translational data add important biological depth. We are seeing evidence of genuine immune reprogramming in the bone marrow, with recovery of healthy progenitor cells and activation of cytotoxic T cell responses. Together, these findings provide a compelling foundation for the randomized Phase 2b BEXERA trial.”

Pre-treatment immune status correlates with depth of clinical response

Translational analyses further demonstrated that bexmarilimab + azacitidine drives meaningful changes in the bone marrow immune landscape. Increases in basophil/mast cell and erythroid progenitor populations were observed in the majority of responding patients, alongside activation of cytotoxic CD8+ T cell responses and reductions in exhausted TIM3+ CD4+ T cells, consistent with immune reprogramming compared to azacitidine activity alone. Baseline immune profiling differentiated responders from non-responders: patients who achieved CR had a higher proportion of CD4+ and CD8+ central memory T cells and a lower proportion of terminal effector memory (TEMRA) T cells prior to treatment, suggesting a more favorable pre-existing immune context in CR responders.

“The findings presented at EHA 2026 represent a vital milestone in our disciplined generation of evidence for bexmarilimab,” said Dr. Juho Jalkanen, Chief Executive Officer of Faron. “The biological evidence of hematological recovery seen with bexmarilimab means that it reduces cancer cells and actively helps a patient’s body rebuild its blood-producing system and capacity to fight the disease, providing hope for a durable recovery where options have been historically limited.”

The safety and tolerability profile remains stable and well tolerated in this elderly, high-risk patient demographic. Backed by this clear translational validation and strong regulatory alignment, the Company is fully on track to initiate its randomized, placebo-controlled Phase 2b clinical trial (designated as the BEXERA trial) in treatment-naïve higher-risk MDS patients during the second half of 2026.

Post‑EHA webcast

Faron will host a live webcast on Monday, 15 June 2026, following the EHA Congress. The webcast will be hosted by Faron management and will feature Dr. Mika Kontro, Principal Investigator of the BEXMAB trial and presenting author of Faron’s EHA poster.

The webcast will focus on the broader clinical and scientific context of the BEXMAB programme and will include a live Q&A session.

Post‑EHA webcast registration: https://faron.videosync.fi/eha-2026

About BEXMAB

The BEXMAB trial is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 11, 2026 at 17:05:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Issue of Treasury Shares to the Issuer X
3. Details of person subject to the notification obligation iv
Name Faron Pharmaceuticals Ltd
City and country of registered office (if applicable) Turku, Finland
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi: 11.6.2026
6. Date on which issuer notified (DD/MM/YYYY): 11.6.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 25,000,000 10.97% 227,881,315
Position of previous notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 25,000,000 10.97%
SUBTOTAL 8. A 25,000,000 10.97%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii x
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Faron Pharmaceuticals Ltd 10.97% 10.97%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
28.5.2026 Company announcement:
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
Place of completion Turku, Finland
Date of completion 11.6.2026

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

Faron Pharmaceuticals Ltd | Company announcement | June 11, 2026 at 17:00:00 EEST

Capitalised terms used in this announcement have the meanings given to them in the announcement made on 28 May 2026 at 15:35 EEST regarding the issue of treasury shares to the Company, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, as announced on 28 May 2026, issued 21,469,427 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First and Second Tranche of Bonds.

In total, 21,469,427 new Treasury Shares in the Company have on 8 June 2026 been registered in the Finnish Trade Register. The treasury shares will rank pari passu in all respects with the existing shares of the Company. Following the registration of new Shares, the aggregate number of ordinary shares in the Company is 227,881,315 and of these shares, the Company holds 25,000,000 shares in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights.

The treasury shares will be listed on First North on 12 June 2026 and on AIM on or around 17 June 2026.

For more information, please contact:

IR Partners, Finland
(Media)

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 10, 2026 at 19:45:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer:
Faron Pharmaceuticals Oy
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation		 City and country of residence:
Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.):
–
5. Date on which the threshold was crossed or reached:
4.6.2026
6. Total positions of person(s) subject to the notification obligation:
% of shares and voting rights
(total of 7.A)		 % of shares and voting rights through financial instruments
(total of 7.B)		 Total of both in % (7.A + 7.B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0.11 10.46 10.57 206,411,888
Position of previous notification (if applicable) 0.10 9.36 9.46
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)		 Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)		 Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)
FI4000153309 0 235,532 0 0.11
– – – – –
– – – – –
SUBTOTAL A 235,532 0.11
B: Financial Instruments according to SMA 9:6a
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash settlement Number of shares and voting rights % of shares and voting rights
Rights of Use n/a n/a n/a 21,333,422 10.34
Swaps 15/10/2027 n/a Cash 243,327 0.12
– – – – – –
SUBTOTAL B 21,576,749 10.46

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☒ Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
Bank of America Corporation
NB Holdings Corporation
BofAML Jersey Holdings Limited
BofAML EMEA Holdings 2 Limited

ML UK Capital Holdings Limited

Merrill Lynch International

Bank of America Corporation

NB Holdings Corporation

BAC North America Holding Company

Bank of America, National Association

Bank of America Corporation

NB Holdings Corporation
Bofa Securities, Inc 10.34% 10.34%
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of
10. Additional information:

Done at London, United Kingdom on 5.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 08, 2026 at 19:30:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer of existing shares: Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of shares
An acquisition or disposal of financial instruments
An event changing the breakdown of shares outstanding X
Other (please specify):
3. Details of person subject to the notification obligation
Name Pentwater Capital Management LP
City and country of registered office (if applicable) Naples, United States
4. Full name of shareholder(s) (if different from 3.)
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached: 04/06/2026
6. Date on which issuer notified (DD/MM/YYYY): 05/06/2026
7. Total positions of person(s) subject to the notification obligation
% of shares outstanding (total of 8. A) % of shares outstanding through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of shares outstanding held in issuer
Resulting situation on the date on which threshold was crossed or reached 3.875746% 3.875746% 8,000,000.00
Position of previous notification (if
applicable)		 4.342441% 4.342441%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedv
A: Shares
Class/type of
shares
ISIN code (if possible)		 Number of shares outstanding % of shares outstanding
Direct Indirect Direct Indirect
SUBTOTAL 8. A
B 1: Financial Instruments as an entitlement to acquire
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Number shares that may be acquired if the instrument is
exercised/converted.		 % of shares outstanding
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash
settlement		 Number of shares % of shares outstanding
Swap Cash Settlement 8,000,000.00 3.875746%
SUBTOTAL 8.B.2 8,000,000.00 3.875746%
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the shares and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(please add additional rows as necessary)		 X
Name % of shares outstanding if it equals or is higher than the notifiable threshold % of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Matthew Halbower
MCH PWCM Holdings Inc.
Pentwater Capital Management LP 3.875746% 3.875746%
10. Additional information
Place of completion Naples
Date of completion 05/06/2026

Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee

Faron Pharmaceuticals Ltd | Company announcement | June 05, 2026 at 13:50:00 EEST

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, announces that, Nasdaq Helsinki Ltd’s Disciplinary Committee has issued their decision and imposed a fine amounting to EUR 30,000 on Faron Pharmaceuticals Oy (“Faron” or “Company”) for breaching the Nasdaq First North Growth Rulebook for Issuers of Shares (“Rules”) regarding the obligation to disclose inside information without undue delay in certain matters in 2024, and good securities market practise in connection with certain public statements made in a media interview in 2024.

The Disciplinary Committee dismissed two of the alleged breaches claimed by the market surveillance, importantly, an allegation that the Company’s administration was not organized in a manner required of a listed company. More details are available in a press release related to the decision published by Nasdaq Helsinki Ltd earlier today.

The Company notes that the cases under evaluation by the Disciplinary Committee were separate from each other and that the only reoccurring topic in the decision was the timing of announcements in AIM London and Nasdaq First North as the release hours are not the same in both markets. The Company notes that it has been listed in both markets since 2019 (in AIM London already since 2015), and it needs to secure simultaneous disclosure of information in both markets in accordance with relevant rules in order to be able to treat its shareholders equally. The Company has followed the same timing praxis to release announcements simultaneously that was established when the Company was listed in Helsinki First North back in 2019. As the Disciplinary Committee now ruled in its decision that disclosures must be done without delay irrespective of the possibility to publish simultaneously in London AIM, the Company will consider its options to fulfil this requirement in dialogue with the stock exchanges.

The Company aims in all of its operations to accurate, explicit and timely communication following all the rules the Company is obligated to follow. The Company takes compliance with the rules very seriously and continuously implements actions to ensure compliance. The fine does not have a material impact on the Company’s operations.

For more information, please contact:

IR Partners, Finland
(Media)
Kare Laukkanen		 +358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
Alyssa Paldo 		 +1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner		 +44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä		 +358 (0)40 555 4727
+358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

Back to top